Part of me says that because PFS allows accelerated approval, they almost certainly would not "stop" the trial now because they need the overall survival data to cement approval.
Let's say they succeed - it wouldn't really stop, but everyone would still be followed for OS. I guess they could censor all OS at the next patient who recurs locally -- from that point on all would be eligible for TDox + RFA. I suspect with another years' maturation the numbers we have now would still show the trend needed for OS.
The other alternative would be keeping the arms intact - not horrible, because the placebo DOES get RFA which does work.
Keep in mind, 5-8 months filing for the NDA and 6 months review means that approval still wouldn't occur until late 2012.
Maybacks Adds Award Winning Show to Its Lineup Discusses Maybacks Opportunity • AHRO • Aug 22, 2024 11:30 AM
North Bay Resources Announces First Gold Concentrate at Mt. Vernon Gold Mine, Assays 12 oz/ton Gold, 17.5 oz/ton Platinum, and 8 oz./ton Silver, Sierra County, California • NBRI • Aug 22, 2024 10:28 AM
All Things Mobile Analytic, Inc. Reports Major Growth with Over $11 Million in Revenue • ATMH • Aug 22, 2024 7:19 AM
Unitronix Announces Strategic Entry into Cryptocurrency Space • UTRX • Aug 21, 2024 10:00 AM
Mawson Finland Provides Update on Exploration Activities at Rajapalot • MFL • Aug 21, 2024 9:06 AM
Avant Technologies to Implement Robust Cybersecurity Measures for AI-Driven Healthcare Solutions • AVAI • Aug 21, 2024 8:00 AM